Related Experiment Video

Updated: Jun 19, 2026

Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
11:09

Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging

Published on: July 13, 2010

39.3K

Design and conduct of theranostic trials in neuro-oncology: Challenges and opportunities

Patrick Y Wen1, Matthias Preusser2, Nathalie L Albert3

  • 1Center For Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.

Neuro-Oncology
|October 5, 2024
PubMed

Insights

Theranostics combines molecular imaging and targeted radionuclide therapy for cancer treatment. Designing clinical trials for brain tumors requires careful consideration of the blood-brain barrier and response criteria.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiology

Background:

  • Theranostics integrates molecular imaging and targeted radionuclide therapy.
  • Approved agents exist for systemic cancers, with potential in neuro-oncology.
  • Brain tumor clinical trials require specific considerations.

Purpose of the Study:

  • To discuss key issues in designing clinical trials for theranostic agents in neuro-oncology.
  • To highlight the need for specialized approaches in brain tumor theranostics.

Main Methods:

  • Review of existing literature and clinical trial methodologies in neuro-oncology.
  • Discussion of challenges specific to brain tumor treatment evaluation.

Main Results:

  • Clinical trials for brain tumors necessitate evaluation of blood-brain barrier penetration.
  • Optimizing eligibility criteria and response assessments (e.g., pseudoprogression) is crucial.
  • Lessons from other neuro-oncology treatments inform theranostic trial design.

Conclusions:

  • Designing effective theranostic clinical trials for brain tumors requires addressing unique challenges.
  • Molecular imaging and careful endpoint selection are vital for success.
  • Further research is needed to optimize theranostic agent application in neuro-oncology.
Keywords:
brain tumorsclinical trialsradionucliidestheranostics

More Related Videos

Stereotactic Intracranial Implantation and In vivo Bioluminescent Imaging of Tumor Xenografts in a Mouse Model System of Glioblastoma Multiforme10:52

Stereotactic Intracranial Implantation and In vivo Bioluminescent Imaging of Tumor Xenografts in a Mouse Model System of Glioblastoma Multiforme

Published on: September 25, 2012

25.6K
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

9.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...